Literature DB >> 31287514

Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans.

Tami L Mark1, William Parish2, Gary A Zarkin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31287514      PMCID： PMC6618771          DOI： 10.1001/jama.2019.6581

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.

Authors:  Shailina Keshwani; Michael Maguire; Amie Goodin; Wei-Hsuan Lo-Ciganic; Debbie L Wilson; Juan M Hincapie-Castillo
Journal:  JAMA Health Forum       Date:  2022-06-24

2.  Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.

Authors:  Kelly E Anderson; Brendan Saloner; Julia Eckstein; Christine E Chaisson; Sarah H Scholle; Lauren Niles; Sydney Dy; G Caleb Alexander
Journal:  Med Care       Date:  2021-05-01       Impact factor: 3.178

3.  Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries.

Authors:  Tami L Mark; William J Parish; Gary A Zarkin
Journal:  JAMA Netw Open       Date:  2020-04-01

4.  Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021.

Authors:  Thuy D Nguyen; Kao-Ping Chua; Barbara Andraka-Christou; W David Bradford; Kosali Simon
Journal:  JAMA Health Forum       Date:  2022-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.